Wilmington PharmaTech announced a $50 million investment to expand its Delaware campus for active pharmaceutical ingredient (API) manufacturing.
Newark, Delaware-based Wilmington PharmaTech said the expansion more than doubles its current API reactor capacity. It adds two new 10,000-liter reactor suites to increase commercial-scale manufacturing capabilities. This supports growing demand for high-quality, U.S.-based manufacturing as the company produces small molecule APIs and peptides.
Wilmington PharmaTech expects the new suites to come online in the third quarter of 2027. Upon completion, it expects to approximately double its site workforce. Headquartered on a 54-acre campus in Newark, the company operates two adjacent, state-of-the-art facilities with extensive cGMP manufacturing capabilities…